Payment overview · 2025
General Payments
$1,545.32
85 reported records · 17 companies
Healthcare provider profile · identity verified
Andrew David Dick, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, IN · NPI 1679570956
Verified facts
What the public records show
CMS Open Payments records show Andrew David Dick, M.D. received $1,545.32 in general payments during 2025 across 85 reported records.
Astellas Pharma US Inc accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $271.09 | 17.5% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $221.83 | 14.3% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $195.30 | 12.6% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $176.76 | 11.4% | 17 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $151.10 | 9.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.09 | 9.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $100.64 | 6.5% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.09 | 3.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.36 | 3.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.86 | 2.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.66 | 1.8% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.75 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.01 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.17 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.10 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.88 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $13.63 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,370.34 | 83 |
| Education | $174.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $151.10 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.36 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.46 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $100.64 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $96.87 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $96.11 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $94.89 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $94.14 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.62 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $76.35 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $71.20 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $64.94 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $64.94 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.83 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.47 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $55.09 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.36 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.96 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $36.05 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.66 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $5.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 869 | 255 |
| Levothyroxine Sodium | Levothyroxine Sodium | 658 | 183 |
| Omeprazole | Omeprazole | 448 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 119 |
| Lisinopril | Lisinopril | 366 | 103 |
| Tramadol Hcl | Tramadol Hcl | 325 | 67 |
| Gabapentin | Gabapentin | 322 | 95 |
| Simvastatin | Simvastatin | 219 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 215 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 63 |
| Metformin Hcl | Metformin Hcl | 185 | 57 |
| Metformin Hcl Er | Metformin Hcl | 177 | 50 |
| Sertraline Hcl | Sertraline Hcl | 176 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 46 |
| Pregabalin | Pregabalin | 154 | 47 |
| Trazodone Hcl | Trazodone Hcl | 153 | 52 |
| Furosemide | Furosemide | 147 | 48 |
| Potassium Chloride | Potassium Chloride | 142 | 45 |
| Alprazolam | Alprazolam | 138 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 42 |
| Prednisone | Prednisone | 134 | 102 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 35 |
| Losartan Potassium | Losartan Potassium | 125 | 39 |
| Glimepiride | Glimepiride | 121 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 57 |
| Meloxicam | Meloxicam | 115 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 102 | 34 |
| Ozempic | Semaglutide | 100 | 24 |
| Carvedilol | Carvedilol | 99 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 26 |
| Alendronate Sodium | Alendronate Sodium | 96 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 28 |
| Clonazepam | Clonazepam | 89 | 13 |
| Buspirone Hcl | Buspirone Hcl | 84 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 22 |
| Montelukast Sodium | Montelukast Sodium | 84 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 23 |
| Azithromycin | Azithromycin | 83 | 63 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 26 |
| Spironolactone | Spironolactone | 82 | 27 |
| Allopurinol | Allopurinol | 79 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 26 |
| Mirtazapine | Mirtazapine | 76 | 21 |
| Mounjaro | Tirzepatide | 76 | 13 |
| Bupropion Xl | Bupropion Hcl | 75 | 21 |
| Temazepam | Temazepam | 75 | 11 |
| Clonidine Hcl | Clonidine Hcl | 74 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 64 |
| Celecoxib | Celecoxib | 71 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 47 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 18 |
| Cephalexin | Cephalexin | 62 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 18 |
| Lorazepam | Lorazepam | 58 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 19 |
| Synthroid | Levothyroxine Sodium | 53 | 16 |
| Eliquis | Apixaban | 51 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 30 |
| Estradiol | Estradiol | 50 | 13 |
| Ezetimibe | Ezetimibe | 50 | 16 |
| Torsemide | Torsemide | 48 | 16 |
| Famotidine | Famotidine | 46 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 15 |
| Chlorthalidone | Chlorthalidone | 43 | 12 |
| Irbesartan | Irbesartan | 41 | 12 |
| Primidone | Primidone | 41 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 19 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Atenolol | Atenolol | 39 | 12 |
| Klor-Con M20 | Potassium Chloride | 39 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Valsartan | Valsartan | 35 | 12 |
| Finasteride | Finasteride | 34 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 11 |
| Doxepin Hcl | Doxepin Hcl | 33 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | 12 |
| Valacyclovir | Valacyclovir Hcl | 30 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 20 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 11 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Naproxen | Naproxen | 25 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 13 |
| Fentanyl | Fentanyl | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Fluocinonide | Fluocinonide | 20 | 11 |
| Risperidone | Risperidone | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Topiramate | Topiramate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Baclofen | Baclofen | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,545.32 · 85 records | Astellas Pharma US Inc | ABRYSVO, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, LEQVIO, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRUMENBA, Tlando, UBRELVY, VRAYLAR, VYNDAMAX, Veozah, XYOSTED, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error